What Is the Difference Between ASV and BiPAP Machines?

ASV (adaptive servo-ventilation) and BiPAP (bilevel positive airway pressure) are both machines that deliver pressurized air through a mask to help you breathe during sleep, but they work in fundamentally different ways and treat different problems. BiPAP delivers two fixed pressure levels, one for breathing in and a lower one for breathing out, and is the workhorse device for conditions like COPD and neuromuscular weakness. ASV is a more sophisticated technology that continuously monitors your breathing pattern and adjusts its pressure support breath by breath, making it the go-to option for central sleep apnea and certain complex breathing disorders. Choosing between them is not a matter of preference; it depends on what is going wrong with your breathing, and in some cardiac patients, the wrong choice can be dangerous.

How the Two Devices Deliver Air Differently

A standard BiPAP machine has two pressure settings. When you inhale, it pushes air at a higher pressure (called IPAP). When you exhale, it drops to a lower pressure (called EPAP), making it easier to breathe out. Those two pressures are fixed or, in some newer auto-BiPAP models, float within a set range. The gap between them, known as pressure support, stays relatively constant. This simple two-tier approach works well when the problem is that your airway collapses (obstructive apnea) or your breathing muscles are too weak to move enough air on their own.

ASV does something considerably more complex. It continuously measures either your airflow or your minute ventilation, calculates a target level of breathing, and then adjusts the inspiratory pressure on a breath-by-breath basis to keep your ventilation stable near that target. When your own breathing effort dips, the machine increases its support. When you are breathing strongly on your own, it backs off. It also applies its pressure support in a pattern deliberately opposite to your own breathing cycle, which is what lets it dampen the waxing-and-waning pattern seen in central sleep apnea. If you stop breathing entirely, the device can deliver breaths at a backup rate to bridge the gap.¹

That anticyclic behavior is the key distinction. BiPAP will give you consistent support whether you need it or not. ASV constantly recalibrates, making it uniquely suited to disorders where the brain’s breathing signals fluctuate unpredictably.

Conditions Where BiPAP Is the Standard Treatment

BiPAP’s primary territory is respiratory failure driven by weak or obstructed breathing mechanics. The clearest example is COPD during a flare-up. When COPD worsens acutely and carbon dioxide builds up in the blood (type II respiratory failure), noninvasive ventilation with BiPAP is one of the most effective interventions available. A Cochrane review of 17 trials found that noninvasive ventilation in this setting cut the need for intubation by roughly 65% and reduced the risk of death by about 46%.² Those are striking numbers, and they explain why BiPAP is a frontline tool in emergency departments and ICUs worldwide.

Beyond acute crises, BiPAP is also prescribed for long-term home use in people with chronic high carbon dioxide levels from COPD. A trial comparing home initiation of chronic noninvasive ventilation to in-hospital initiation found that both approaches reduced carbon dioxide levels and improved quality of life, with home setup working just as well and costing less than half as much.³

BiPAP also serves people with neuromuscular diseases like ALS, muscular dystrophy, and spinal cord injuries, where the muscles responsible for breathing gradually weaken. In ALS specifically, different BiPAP modes have been compared. Volume-assured pressure support, a hybrid mode where the machine targets a set tidal volume, produced somewhat larger breaths than standard pressure-preset BiPAP in one study of 271 patients, though usage hours and survival were similar between groups.⁴ Patients with bulbar-onset ALS, who have weakness in the throat and mouth muscles, sometimes struggle more with advanced auto-adjusting modes because those modes can increase upper-airway instability.⁵

Why Central Sleep Apnea Needs Something Different

To understand why ASV exists, you need to know what central sleep apnea actually is. In obstructive sleep apnea, the airway physically collapses. In central sleep apnea, the airway stays open but the brain intermittently stops sending the signal to breathe. The most well-known pattern is Cheyne-Stokes respiration, where breathing gradually deepens, then gradually fades away, then stops completely for several seconds before the cycle repeats. This happens because the respiratory control system becomes unstable. In people with heart failure, for example, the brain overreacts to carbon dioxide changes, breathing too vigorously and driving carbon dioxide below the threshold that triggers breathing, causing a pause.⁶

A fixed-pressure device like standard BiPAP cannot solve this problem effectively because the problem is not a lack of pressure support. It is a feedback loop in the brain’s breathing center. BiPAP will dutifully push the same amount of air regardless of whether the patient is in the deep-breathing phase (where they do not need much help) or the no-breathing phase (where they need the machine to take over). ASV’s anticyclic algorithm is designed precisely for this scenario. When the patient breathes deeply, ASV dials its support down, preventing the excessive ventilation that drives carbon dioxide too low. When breathing fades or stops, ASV ramps up and delivers breaths at a backup rate, preventing the pause from lasting long enough to cause oxygen drops or arousals.

Treatment-Emergent Central Apnea and the Switch From CPAP

Some people develop central sleep apnea only after they start using CPAP for obstructive sleep apnea. This phenomenon, called treatment-emergent central sleep apnea, occurs in roughly 8% of patients during CPAP titration studies.⁷ For many of these patients, the central events resolve on their own within weeks to months of continued CPAP use. For those whose central apnea persists, a switch to ASV is one of the main options.

A large database analysis tracking patients who switched from CPAP to ASV found encouraging results. Before the switch, those patients had a CPAP adherence rate of about 63%. After switching to ASV, their adherence climbed to roughly 77%, with average nightly use of about 5.7 hours, which was actually higher than the 5.3 hours seen in patients who had been on CPAP alone all along.⁸ The improved adherence likely reflects the fact that ASV is better matched to these patients’ underlying breathing disorder, making the therapy feel more comfortable and less like fighting against the machine.

The Heart Failure Safety Concern That Changed Everything

ASV seemed like a natural fit for heart failure patients with central sleep apnea, and for years it was used that way. Then the SERVE-HF trial, one of the largest studies of ASV ever conducted, delivered a result nobody expected. In heart failure patients with reduced pumping function (ejection fraction of 45% or below) and moderate-to-severe central sleep apnea, ASV not only failed to help but actually increased the risk of dying. All-cause mortality was about 28% higher in the ASV group, and cardiovascular death was 34% higher, compared with patients who received standard medical care without ASV.⁹

A follow-up analysis of the same trial data confirmed that the harm was linked to actual ASV use, not just being assigned to the ASV group. Patients who used the device more did not fare worse than those who used it less within the ASV arm, but the overall signal of increased cardiovascular death held up regardless of how the data were sliced.¹⁰

The working theory for why ASV was harmful in this population centers on the role central apnea may play in a failing heart. Cheyne-Stokes respiration in heart failure might actually be a compensatory mechanism. The periodic pauses in breathing could give the heart intermittent rest from the work of breathing, and suppressing those pauses with ASV could increase cardiac workload at a time when the heart cannot handle it. This remains debated, but the clinical consequence is clear: ASV is now contraindicated in heart failure patients with severely reduced ejection fraction and significant central sleep apnea.

Where ASV May Still Be Safe in Heart Failure

The SERVE-HF findings do not apply uniformly to every heart failure patient. The danger signal was specific to patients whose hearts pumped poorly, with ejection fractions at or below 45%. For patients with heart failure but preserved pumping function (called HFpEF, where the ejection fraction is above 45%), the picture looks different. Updated guidelines from the American Academy of Sleep Medicine issued an “Option” level recommendation allowing ASV in heart failure patients whose ejection fraction is above 45% or whose central sleep apnea is mild.¹¹

Some emerging data support this distinction. A study of heart failure patients with preserved ejection fraction found that heart failure hospitalizations dropped significantly after ASV was introduced, from a median of one hospitalization in the prior year to zero in the year after starting ASV.¹² The CAT-HF trial, though underpowered overall, also found a signal suggesting benefit specifically in the preserved ejection fraction subgroup.¹³ These are preliminary findings from relatively small studies, so the evidence is far from settled. But the trajectory of the research is toward a more nuanced view: ASV may genuinely help heart failure patients whose main problem is not a severely weak heart muscle.

How ASV Performs for Sleep Quality and Daytime Function

One reasonable question is whether ASV actually makes people feel better, or whether it just improves numbers on a sleep study. The answer is mixed. A systematic review found that while ASV effectively reduced the number of central apnea events, it was not clearly superior to CPAP, BiPAP, or even supplemental oxygen when it came to polysomnography-measured sleep quality, subjective daytime sleepiness, or quality of life in heart failure patients with Cheyne-Stokes respiration.¹⁴ That’s a humbling finding for a device that costs significantly more than those alternatives.

In patients with central sleep apnea from causes other than heart failure, the subjective improvements are more encouraging. One study using a fully automated ASV algorithm found that daytime sleepiness scores dropped substantially over three months, from an average of about 13 (which indicates excessive daytime sleepiness) to about 8 (which is near normal), with the breathing event index staying well controlled. Average nightly use in that study was about four hours, which is consistent with what most positive airway pressure studies report.¹⁵

Insurance Coverage and Access Barriers

Getting insurance to cover ASV can be a frustrating process. Medicare and many private insurers have narrow coverage criteria that require patients to first try CPAP and demonstrate that it has failed to control their central apnea before ASV will be authorized. A joint technical expert panel from several major respiratory and sleep organizations highlighted how these rules can actually harm patients. The coverage criteria sometimes demand near-complete elimination of obstructive breathing events on CPAP or basic BiPAP before a patient can qualify for ASV or BiPAP with a backup rate, even when those simpler devices are clearly not working or require intolerable pressures.¹⁶

The cost difference between the devices is also worth knowing. A basic BiPAP machine typically costs somewhere in the range of $1,500 to $3,000 out of pocket, while ASV devices generally run $3,000 to $7,000. Insurance reimbursement rates and out-of-pocket costs vary widely depending on your plan, whether the device is rented or purchased, and whether your provider handles the prior authorization paperwork effectively. If your sleep specialist recommends ASV and your insurer denies it, asking for a peer-to-peer review, where your doctor speaks directly with the insurance company’s medical reviewer, is often the most productive next step.

Opioid-Induced Central Apnea

Chronic opioid use is one of the more common non-cardiac causes of central sleep apnea. Opioids suppress the brainstem’s respiratory drive, leading to irregular breathing, prolonged pauses, and a distinctive pattern called ataxic or Biot’s breathing that differs from the smooth waxing-and-waning of Cheyne-Stokes. Both ASV and BiPAP have been reported as effective for opioid-induced central apnea in some patients, though the evidence base is limited and the best device choice often comes down to individual titration results.¹⁷

The clinical challenge here is that opioid-induced central apnea often coexists with obstructive events, and the balance between the two can shift over time as opioid doses change. ASV’s ability to adapt breath by breath gives it a theoretical advantage in this fluctuating landscape. But the heart failure contraindication still applies: if someone on chronic opioids also has heart failure with a low ejection fraction, ASV carries the same risks seen in the SERVE-HF trial. These patients need especially careful evaluation.

Pressure Settings and Fine-Tuning

Both BiPAP and ASV require thoughtful pressure titration, but the parameters you can adjust differ. With BiPAP, the main variables are the inspiratory and expiratory pressures and, if the device has a timed backup mode, the backup respiratory rate. With ASV, you set a minimum and maximum inspiratory pressure support range plus the expiratory pressure, and the device automatically adjusts the actual support delivered within those boundaries.

The expiratory pressure setting on ASV may matter more than previously appreciated. A study examining heart failure patients on ASV found that those with expiratory pressure settings below 5 cmH2O showed a trend toward lower two-year mortality compared with those at higher settings, with roughly 26% versus 38% dying over two years. The difference did not quite reach statistical significance, but the direction of the trend suggests that keeping expiratory pressures low may reduce cardiac strain.¹⁸ For clinicians titrating ASV in cardiac patients, this is the kind of detail that could influence how aggressively they set the expiratory pressure.

Pediatric and Unusual Uses

ASV is primarily an adult therapy, and there is very little published data on its use in children. One documented case involved an adolescent with epilepsy whose vagus nerve stimulator, a device implanted to control seizures, was causing central sleep apnea as a side effect. BiPAP was tried first and failed to control the central events. When ASV was titrated instead, it successfully treated both the obstructive and central components of the patient’s disordered breathing, and the patient reported improved daytime functioning.¹⁹ This is a single case report, not a basis for broad recommendations, but it illustrates that there are niche situations where ASV fills a gap that BiPAP cannot.

Other unusual indications that show up in sleep medicine practice include central apnea caused by stroke, brain tumors affecting the brainstem, or high-altitude periodic breathing. In these scenarios, ASV is typically tried when simpler therapies have failed, and the evidence is mostly case-level. The unifying principle is that whenever the problem is an unstable breathing pattern driven by the brain rather than the airway, ASV’s adaptive algorithm has a mechanical advantage over BiPAP’s fixed pressure delivery.

Remote Monitoring and Staying on Therapy

Modern ASV and BiPAP devices both come equipped with wireless modems that transmit usage data, mask leak measurements, and residual breathing event counts to your provider’s monitoring platform. This telemonitoring has become a meaningful part of how therapy is managed. A study of one large healthcare provider’s database found that patients who used an interactive engagement tool alongside their positive airway pressure therapy used their devices for four or more hours on about 77% of nights, compared with 63% in a group receiving standard proactive care. Therapy abandonment was also significantly lower in the engaged group.²⁰

If you are on either device and not using a companion app or patient portal, it is worth asking your equipment provider whether one is available. The feedback loop of seeing your own data, leak trends, and event counts can be motivating, and it gives your sleep team a way to catch problems like a deteriorating mask fit or changing pressure needs before your next clinic visit.